|
April 17, 2012
Dear Friend,
I'm happy to share some breaking news from the Early/Expanded Access Committee, which Dr. Mark Moyad and I co-chair, and includes members of other prostate cancer advocacy organizations, researchers and advocates. Alpharadin (Radium 223), a new drug meant to prolong survival in advanced prostate cancer, is now available in New Orleans, with future potential sites including AZ, CA, FL, MA, MO, NV, PA, SC, TX and WV. For more on
Alpharadin, read Dr Sartor's article on page 9 of PAACT's March 2012 newsletter.
There is no placebo and no cost for this Alpharadin trial. Check with the trial site for any other costs:
Radium-223 Chloride in
Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone
Metastases
Basic Eligibility Criteria
- CRPC/HRPC - on hormone therapy with progressive disease
- At least 2 bone metastases - blastic (sclerotic), not lytic
- Some amount of pain/bone pain (must be taking daily meds – even if it’s Tylenol)
- No mets to lung, liver, or brain• HGB 10.0 or higher
- Previously treated with Taxotere (or have refused Taxotere – patient’s choice)
- 4 weeks since chemo, and No chemo currently planned
- No abiraterone (Zytiga) while on Alpharadin - previous OK
- No previous extensive radiation to bone (> 25% of bone marrow), and no previous Quadramet or Strontium 89
|
If you think you fit the above criteria, contact Patrick Cotogno, or for further screenings, Oliver Sartor MD at:
Tulane University
1415 Tulane Ave. HC-62
New Orleans, LA 70112
Phone: (504) 988-2735
Principle Investigator: osartor@tulane.edu
Study Coordinator: pcotogno@tulane.edu
Please
feel free to forward this message along to other men you know who are dealing
with painful prostate cancer.
Sincerely,
|
Thomas Kirk
President & CEO
Us TOO International
Downers Grove, IL 60655
Office: 630-795-1002
Toll Free: 800-808-7866
tom@ustoo.org
|
|
|
